Results 241 to 250 of about 94,242 (328)

kcnb1 loss of function in zebrafish causes neurodevelopmental and epileptic disorders associated with γ‐aminobutyric acid dysregulation

open access: yesEpilepsia, EarlyView.
Abstract Objective KCNB1 encodes an α‐subunit of the delayed‐rectifier voltage‐dependent potassium channel Kv2.1. De novo pathogenic variants of KCNB1 have been linked to developmental and epileptic encephalopathies (DEEs), diagnosed in early childhood and sharing limited treatment options.
Lauralee Robichon   +7 more
wiley   +1 more source

Prevalence, clinical characteristics, and risk factors for psychosis in people with epilepsy: A multicenter retrospective cohort study

open access: yesEpilepsia, EarlyView.
Abstract Objective We aimed to assess the prevalence, clinical characteristics, and risk factors for psychosis in a cohort of people with epilepsy in West China. Methods We used retrospective information from databases of three tertiary epilepsy centers, which included follow‐up records from 2006 onward.
Sisi Shen   +6 more
wiley   +1 more source

Gamma-Aminobutyric Acid (GABA) as a Defense Booster for Wheat against Leaf Rust Pathogen (Puccinia triticina). [PDF]

open access: yesPlants (Basel)
Khalil HB   +9 more
europepmc   +1 more source

Sustained rescue of seizure control in patients with highly refractory chronic epilepsy using empiric immunotherapy

open access: yesEpilepsia, EarlyView.
Abstract Objective Following emerging evidence of autoimmune‐associated seizures in medication‐refractory epilepsy, we began offering a trial of immunotherapy to selected patients. Here, we review this approach's treatment response, predictive clinical features, and utility.
Elisabeth Doran   +4 more
wiley   +1 more source

The human photosensitive epilepsy model for clinical proof‐of‐principle trials of novel antiseizure medications: 2. Analysis of drug trials and predictive value of the model

open access: yesEpilepsia, EarlyView.
Abstract Clinical development of novel antiseizure medications (ASMs) would benefit from an early proof of principle (POP) model. The photosensitivity model, which uses the photoparoxysmal electroencephalographic response (PPR) as a surrogate of seizures, is currently the only human model that allows POP trials of investigational compounds after a ...
Wolfgang Löscher   +1 more
wiley   +1 more source

Home - About - Disclaimer - Privacy